Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
September 26, 2019 08:00 ET
|
Immutep Limited
Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002,...
Immutep to Receive £4M Milestone Payment From GSK
September 23, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Japanese Patent Grant for LAG525 Antibody
September 17, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody...
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
August 22, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Completes A$6M Entitlement Offer
August 06, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the completion of its fully underwritten pro rata...
Operational Update
July 26, 2019 08:00 ET
|
Immutep Limited
TACTI-002 patient recruitment updateThree patients now enrolled and dosed in INSIGHT-004, recruitment ongoingSignificant eftilagimod alpha clinical data expected in coming months: º AIPAC Phase II -...
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
July 09, 2019 08:00 ET
|
Immutep Limited
NEW YORK, July 09, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “Company”), an Australian biotechnology company developing novel immunotherapy treatments for...
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
June 25, 2019 08:00 ET
|
Immutep Limited
226 patients with metastatic breast cancer have been enrolled in the AIPAC studyCombination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with...
Immutep to Host Key Opinion Leader Call
June 24, 2019 14:36 ET
|
Immutep Limited
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and...
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
June 21, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, June 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...